In the present work, we investigated the antinociceptive effect of gabapentin in a chronic myositis model and its interference in spinal glial cells. Chronic myositis was induced by injection of Complete Freund Adjuvant (CFA) into the right gastrocnemius (GS) muscle of rats and tests for evaluating mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia were performed. Pharmacological treatment with gabapentin was administrated intrathecally and 100 μg and 200 μg doses were tested. For analyzing astrocytes and microglia in the spinal cord, immunochemistry assay was performed. It was found that gabapentin 200 μg reverted CFA-induced chronic muscle pain bilaterally, in all applied tests and it was able to attenuate microglial but not astrocytes activation in the dorsal horn of spinal cord. In conclusion, gabapentin was able to inhibit hyperalgesia and allodynia in chronic myositis and also to attenuate spinal microglial activation. Therefore, gabapentin could be used as treatment for targeting chronic muscle pain.
Introduction
Researchers have pointed musculoskeletal pain as one of the most prevalent types of pain in the population and one of the hardest types of pain to treat (Magni et al., 1990; Teixeira et al., 2001; Miranda et al., 2012) . Muscle pain can arise from disorders such myofascial pain, fibromyalgia, myositis and strain. The muscle injury then leads to sensitization of peripheral nociceptors and dorsal horn neurons, transmitting nociceptive information to higher brain centers and results in hyperalgesia and allodynia (Hoheisel et al., 1994 (Hoheisel et al., , 1998 Sluka et al., 2001; Schafers et al., 2003) .
Studies have demonstrated that glia cells are involved in nociception, especially in chronic conditions (Watkins and Maier, 2003a; Tsuda et al. (2005) ; Milligan and Watkins (2009) by releasing proinflammatory substances, playing a relevant role in the transmission of nociceptive information (Watkins and Maier, 2003a; Watkins et al., 2003b; Marchand et al., 2005) and leading to allodynia and hyperalgesia (Sweitzer et al., 1999; Milligan et al., 2000) . Studies also demonstrated that chronic myositis induced into the muscle tissue leads to morphological and functional alterations of astrocytes and microglia (Tenschert et al., 2004; Chacur et al., 2009) .
Gabapentin, an anticonvulsant with few side effects, has been reported to have antinociceptive effect in chronic pain states, such as diabetes, neuropathic pain and arthritis (Yang et al., 2012; Ali et al., 2015; Park et al., 2015; Zvejniece et al., 2015) . It is thought that its mechanism of action is by reducing neural hyperexcitability by binding to the α2/δ−1 subunit of dependent voltage calcium channel present in neurons (Cheng and Chiou, 2006; Tsukumo et al., 2011; Zhou and Luo, 2014; Morioka et al., 2015) . However, its use in chronic musculoskeletal pain remains unclear. In the present study we induce chronic myositis to investigate whether gabapentin is able to reverse chronic muscle pain and interfere in astrocytes and microglial cells.
Materials and methods

Animals
Male Wistar rats (60-80 days old; 200-220 g; Institute of Biomedical Sciences Central Biotery, University of Sao Paulo) were housed with food and water available ad libitum at room temperature of 22 ± 2°C.All rats were maintained on a 12:12 h light/dark cycle (lights on at 07 h) and were given two days to adapt to the experimentation room. All experimental procedures were conducted in accordance with the University of São Paulo Institutional Animal Care Committee (certification 47/2013). Animals were handled considering the principles and animal laboratory guide involving pain and nociception (Zimmermann, 1983) .
Induction of chronic myositis
Chronic myositis was induced by one single injection of Complete Freund's Adjuvant (CFA) (M. butyricum, Difco) into the animals right gastrocnemius (GS) muscle (150 μg /300 μl) and the analyses were performed 12 days after the injection. Previous studies have shown that the following doses and time point chosen were able to induce a chronic muscle pain model in animals. Naive animals were used as control (Chacur et al., 2009 ).
Pharmacological intervention
Single Gabapentin (GBP -Neurontin®/Ache) injection was administered intrathecally 13 days after the CFA-induced injury. Gabapentin injection doses used were 100 μg and 200 μg into 50μLsterile saline 0.9% (vehicle). A control group received equivolume injection of vehicle intrathecally (Chacur et al., 2009; Yamama et al., 2010; Dias et al., 2012; Cheng and Chiou, 2006) . Animals were anesthetized through inhalation with isoflurane via loose-fitting coneshaped masks and puncture of the spinal subarachnoid space was performed. A 29-gauge needle was introduced through the shaved skin into the L5-L6 intervertebral space. The correct positioning of the needle was assured by a tail flick reaction. Then the drug was administered and the needle was carefully removed (Mestre et al., 1994) .
Behavioral tests
Blind and randomized behavioral tests were applied before any procedures (Baseline -BL) and repeated on the 6thand 12thdays after CFA injection. In order to analyze the drug action, behavioral tests were repeated 1, 3, 5, 7 and 24 h after gabapentin administration. All behavioral tests were measured in both ipsilateral and contralateral hindpaw.
Mechanical hyperalgesia
For assessing the animals' mechanical threshold the Electronic Von Frey (IITCInc.) was used, according to the modified method described by Chacur et al. (Chacur et al., 2009) . In this test, a tip was pressed with increasing force to the medial head of the GS muscle in the mediolateral direction until the limb withdrawal response was observed. Therefore, the applied force in grams (g) was considered as nociceptive threshold.
Thermal hyperalgesia
For determining the animals thermal sensitivity the plantar test described by Hargreaves was used (Hargreaves et al., 1988) . The animals were placed in enclosure compartments and positioned on a platform under an infrared heat source (Ugo Basile). Latency to paw withdrawal and infrared intensity were recorded automatically in seconds (s) and was defined as the paw withdrawal latency (PWL) and nociceptive threshold. A cutoff time of 30 s was defined as time limit to the heat exposure.
Mechanical allodynia
In order to assess the animals tactile sensitivity, the Von Frey Hairs test described by Chaplan et al. was used (Chaplan et al., 1994) . A logarithmic series of 10 calibrated Semmes-Weinstein monofilaments (Ugo Basile) were applied to the plantar surface of the animals hind paw. Log stiffness of the hairs was determined and ranged from manufacturer designated 3.61 (0.407 g) to 5.18 (15.136 g) filaments, all applied at maximum 10 s to standardize the time. The thinner filament (0.407 g) was primarily applied to find the threshold stimulus intensity required to elicit a paw withdrawal response. The experiment was carried out, increasing the filament thickness in case the animal did not respond twice to the previous filament on the scale. Failure to respond to the thicker filament, corresponding to the strongest stimulus (15.136 g) was considered to be the cutoff value.
Immunohistochemistry
On the 14th day (24 h after gabapentin injection), animals were deeply anesthetized with injection of ketamine and xylazine (5 mg/ 100 g; i.p). After animals were completely unresponsive, they were transcardially perfused with saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). The L4-L6segment of spinal cord was rapidly collected and postfixed for 4 h and transferred to 30% sucrose in PB for 24 h. The spinal cord was horizontally sectioned using a freezing microtome at 30 µm thickness.
For the detection of astrocytes and microglia in spinal cord, floating sections were incubated with GFAP (Monoclonal Anti-Glial Fibrillary Acidic Protein, Clone G-A-5 -Sigma-Aldrich)or OX-42 (Purified mouse anti-rat Cd11b/c monoclonal antibody -BD Biosciences Pharmigen) diluted 1:1000 in PB containing 0.3% Triton X-100% and 5% normal goat serum per overnight at 24°C. Following washing, sections were incubated with biotinylated secondary antibody (1:200, Jackson ImmunoResearch) diluted in 0.3% triton X-100 and washed in PB. Then, incubated with avidin-biotin-peroxidase complex (ABC, Vector Laboratories, Burlingame) for 1 h, labeling with peroxidase using the chromogen 3, 3′-diaminobenzidine (DAB -Sigma-Aldrich) and hydrogen peroxide solution 0.01% in PB.
The immunoreactivity of both sides of lumbar spinal cord, specifically lamina I and II of the dorsal horn were examined by light microscopy (Nikon Eclipse; ACT-1 Program). The specific lamina were choose based in previous articles showing that fibers from gastrocnemius muscle were conducting to lamina I and lamina II % (Ling et al., 2003; Panneton et al., 2005) . Images were subjected to quantitative analysis involving ten sections from each lumbar spinal cord processed from each experimental and control animal. All images were quantified with the identical software and imaging parameters (Image J Program). Data were reported as the numbers of glial-positive cells. For the comparative analyses, the controls were considered as 100% (Chacur et al., 2009 ).
Statistical analyses
All data were presented as mean ± SEM. Statistical analyses consisted of Two-way ANOVA for behavioral tests and One-way ANOVA for immunohistochemistry assays. Both analyzes were followed by Bonferroni test, using Prism 5.01 (GraphPad Software Inc., CA, USA). In all cases, differences between group means were considered statistically significant if p < 0.05 (Sokal and Rohlf, 1981) .
Results
Standardization of treatment with gabapentin
For determining the dose to be used in the animals' treatment, we started with two different gabapentin doses. Therefore, the initial doses tested were 100 μg and 200 μg of gabapentin, injected intrathecally. After its administration, the electronic Von Frey test was performed to assess the animals'nociceptive threshold. The behavior test was conducted before (BL), 6 and 12 days after CFA injection and once again after intrathecal application of gabapentin (1-24 h after). The results showed that the 200 μg dose was more effective in reversing the nociceptive behavior compared to lower dose (p < 0.001 for the 1st and 3rd hour compared to the Inflamed GS muscle group). The higher dose of gabapentin increased the nociceptive threshold in the first and third hours after administration. Later, in the 5th and 7th hour, the antinociceptive effect gradually decreases. At 24th hour time point, the drug was ineffective (Fig. 1) . No statistical difference was observed within 100 μg of gabapentin during the analyzed time. Furthermore, Inflamed GS muscle group remained with nociception throughout all the experimentation period (p < 0.05 for the 6th day and 5th hour, p < 0.01 for the 24th hour and p < 0.001 for the 12th day and 1st, 3rd and 7th hour). Naive group maintained its nociceptive threshold stable over time.
Gabapentin inhibits pain behavioral responses of rats with chronic myositis
After treatment standardization, behavioral tests for assessing thermal and mechanical hyperalgesia and tactile allodynia were carried out. Once again, tests were applied on the 1st, 3rd, 5th, 7th and 24th hours after drug administration. We showed that 200 μg of gabapentin improved the nociceptive threshold of rats with chronic myositis, on the ipsilateral side, five hours after treatment in allodynia and thermal tests when compared to the Inflamed GS muscle + saline group ( Fig. 2A  and B, respectively ). An increase was demonstrated in the nociceptive threshold in the mechanical test until the seventh hour after gabapentin administration when compared to Inflamed GS muscle+ saline group (Fig. 2 C) .
When the contralateral hindpaw was analyzed, it was also observed a decrease of nociceptive threshold after CFA injection for thermal and mechanical tests (Fig. 2B and C) . On the other hand, no alteration for allodynia test was observed after CFA injection ( Fig. 2A) . After gabapentin treatment, the contralateral hyperalgesia was also inhibited during three hours after administration (Fig. 2B and C) . Therefore, behavioral test evidenced that the intervention with gabapentin was able to reverse tactile allodynia ( Fig. 2A) and bilateral thermal and mechanical hyperalgesia (Fig. 2Band C) in animals with CFA-induced chronic muscle pain.
Effect of gabapentin on glial markers in dorsal horn of lumbar spinal cord of rats with CFA-induced chronic muscle pain
Immunohistochemistry assays were performed in order to was analyze the L4-L6 segment of lumbar spinal cord, specifically lamina I and II of the dorsal horn, to verify changes in glial activation (Ling et al., 2003; Panneton et al., 2005) . The images of the lumbar spinal cord showed an increase in the astrocytes and microglia markers (Figs. 3 and 4, respectively) on the ipsilateral dorsal horn of animals with CFA-induced chronic muscle pain, compared to naive animals. Regarding the contralateral side, we did not find statistical differences for both glial markers. After gabapentin treatment, we observed a decrease in microglia ( Fig. 4B and C) but not in astrocytes ( Fig. 3B and  C) on the ipsilateral side of the rats spinal cords, in comparison to the CFA + saline group (control). Once again, no changes were observed in the contralateral side of the spinal cord for both glial markers. Nociceptive threshold measured by Electronic Von Frey test (expressed in grams) was determined before (BL), on 6th, 12th day after CFA injection. On day 13 (13d) gabapentin was injected and the nociceptive test was applied 1, 3, 5, 7 and 24 h after pharmacological treatment. Results represent the mean ± SEM of 4 animals per group. #p < 0.05 compared between Inflamed GS muscle and NAIVE and *p < 0.05 compared between Inflamed GS muscle +GBP 200 μg and Inflamed GS muscle groups. ) and Von Frey electronic test (expressed in grams) measured before (BL), on 6th and the 12th day after CFA. On day 13 (13d) gabapentin was injected intrathecally and behavioral tests were applied bilaterally 1, 3, 5, 7 and 24 h after pharmacological treatment injection. Results represent the mean SEM ± 8-10 animals per group. # p < 0.05 for comparison between NAIVE and Inflamed GS muscle + saline groups. * p < 0.05 compared between Inflamed GS muscle + GBP and Inflamed GS muscle + saline groups. † p < 0.05 for comparison between naive and contralateral GS muscle + saline groups. & p < 0.05 for comparison between contralateral GS muscle+ GBP and contralateral GS muscle + saline groups.
Discussion
Muscle tissue is a very common site of pain, and probably, everyone will experience muscle pain at least once in life. Indeed, chronic muscle pain represents a high economic cost and does not respond well to conventional interventions, affecting people's quality of life. Thereby, researchers have employed substances including Freund's Complete Adjuvant as an experimental model to induce chronic myositis for the Fig. 3. -Immunoreactivity for astrocytes in the dorsal horn of lumbar spinal cord. Astrocytes immunoreactivity is revealed by immunohistochemical for GFAP staining. A) Quantification of astrocytes in the dorsal horn of the spinal cord in both ipsilateral and contralateral sides pointing the standard rectangular area used for quantification. B) The images provide representative photomicrographs of ipsilateral and contralateral dorsal horn microglia staining from different groups in 40x magnification. C) Bar graph representing the results of the image analysis, showing the increase of GFAP labeling on the ipsilateral dorsal horn of animals injected with CFA when compared to naive rats, used as control. No differences were found after gabapentin (GBP) was administrated. Results represent the mean SEM ± 5 animals per group. *p < 0.05 for comparison among CFA + saline and the others. study of muscle pain without induce animals' motor coordination problems (Hoheisel et al., 1998 (Hoheisel et al., , 2013 Reinert et al., 1998; Chacur et al., 2009) . In this study, we demonstrate that CFA-induced chronic myositis into the gastrocnemius muscle decreases the nociceptive threshold of rats in behavioral tests and produces mechanical and thermal hyperalgesia as well as allodynia. These results corroborate with studies that observed bilateral hyperalgesia in rats with musculoskeletal pain induced by acidic saline and carrageenan (Sluka et al., 
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European Journal of Pharmacology 799 (2017) 111-117 2001; Radhakrishnan et al., 2003) . It is known that glia cells participate in nociceptive processes and release substances such as prostaglandins, glutamate, arachidonic acid, nitric oxide and cytokines, and are also involved in nociceptive hypersensitivity and transmission (Watkins and Maier, 2003a; Tsuda et al., 2005; Milligan and Watkins, 2009; Kobayashi et al., 2015; Old et al., 2015) . However, the involvement of these cells in animals with chronic muscle pain has been rarely studied. In our study, a significant increase of astrocytes and microglia was found in the spinal cord after CFA-induced chronic myositis, indicating a possible modulation of these cells in chronic muscle pain. Our results corroborate with prior studies that showed changes in spinal glial cells of rats with chronic myositis (Tenschert et al., 2004; Chacur et al., 2009 ).
Thus, we chose gabapentin as a potential treatment for its antinociceptive effects (Zhang et al., 2009 Krzyzanowska et al., 2011; Allchorne et al., 2012; Mimenza Alvarado and Aguilar Navarro, 2016) , as well for its efficacy shown in clinical chronic pain (Rowbotham et al., 1998; Cheng and Chiou, 2006; Dolgun et al., 2014; Beladi Mousavi et al., 2015; Atkinson et al., 2016; Lewis et al., 2016; Robertson and Marshman, 2016) . Studies have demonstrated that gabapentin may reduce glutamate, substance P, NF-κB, CGRP and IL-6 inhibiting pain by binding the α2/δ−1 subunit of dependent voltage calcium channel present in neurons, (Fink et al., 2000; Yaksh, 2006; Park et al., 2008; Quintero et al., 2011; Kukkar et al., 2013) . Besides, it is known that intrathecal gabapentin only impairs animals motor functions in high doses (Kang et al., 2014) .
Pharmacological treatment with gabapentin was performed intrathecally, an administration route that consists of injecting substances directly into the cerebrospinal fluid, in the subarachnoid space, and wherein its efficacy could be most effective (Cheng and Chiou, 2006) . Doses tested were 100 μg and 200 μg and it was found that 200 μg of gabapentin is more efficient in improving pain responses in all performed behavioral tests and for a longer time, corroborating with a previous study with persistent musculoskeletal pain (Kang et al., 2014) . In this study, gabapentin was tested as a treatment for chronic muscle pain by controlling hyperalgesia and allodynia and it was found that intrathecal gabapentin administration quickly reversed mechanical and thermal hyperalgesia and tactile allodynia of rats with CFAinduced chronic myositis.
Gabapentin 200 μg increased the nociception threshold of rats at least five hours after intrathecal administration, decreasing tactile allodynia and thermal hyperalgesia, and further decreasing mechanical hyperalgesia at the seventh hour after treatment. The same results were observed in the contralateral hindpaw after treatment, showing that gabapentin also led to a nociception enhancement during three hours after administration. These behavioral tests showed that the intervention with gabapentin 200 μg intrathecally injected was able to inhibit bilateral pain behavior in animals with chronic myositis.
Indeed, it was observed that gabapentin was able to inhibit microglia cells in the dorsal horn of spinal cord, reducing its immunoreactivity in the ipsilateral side of the dorsal horn of the spinal cord. Our results corroborates with other studies that found that gabapentin reduces spinal microglial activation in other pain models such as monoarthritic and diabetic rats (Wodarski et al., 2009; Yang et al., 2012) , but no changes were found in astrocytic reactivity.
In conclusion, we suggested that astrocytes and microglia cells are related to the modulation of chronic muscle pain and that gabapentin is able to reverse bilateral hyperalgesia and allodynia in a chronic myositis model, as well as microglia immunoreaction. Therefore, gabapentin could be used as a potential therapy for chronic muscle pain.
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